Navigation Links
Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
Date:10/2/2007

Corrected Announcement Follows

NEW YORK, Oct. 2 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that I. Craig Henderson, MD, the Company's President, will present an overview of the Company's cancer pipeline at the upcoming William Blair & Company Small-Cap Growth Stock Conference in New York City. Dr. Henderson's presentation will take place on Wednesday, October 3rd at 12:00 noon ET.

Dr. Henderson's presentation will be webcast live and will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx's lead compound under development is Sulonex(TM) (sulodexide), previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex is in a pivotal Phase III and Phase IV clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing Zerenex(TM), an oral, iron- based compound that has the capacity to bind phosphate and form non-absorbable complexes. Zerenex is currently in Phase II clinical development for the treatment of hyperphosphatemia (elevated serum phosphorous levels) in patients with end-stage renal disease. Keryx is also developing clinical-stage oncology compounds, including KRX-0401 (perifosine), a novel, first-in-class, oral modulator of Akt, a pathway associated with tumor survival and growth, and other important signal transduction pathways. KRX- 0401 is currently in Phase II clinical development for multiple tumor types. Keryx also has an active in- licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

KERYX CONTACT:

Lauren Fischer

Director - Investor Relations

Keryx Biopharmaceuticals, Inc.

Tel: 212.531.5965


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Onchocerciasis: Presentation And Treatment
2. Researchers Warn That Routine Physical Examination Could Miss Breech Presentation
3. New lease of life for asthmatics by Accentia Biopharmaceuticals
4. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
5. IDM Pharma Presents Preliminary Results of Melanoma Vaccine Clinical Trial
6. Living Liver Donor Who Saved Life of Mother-in-law Represents Cedars-Sinai in Rose Parade
7. Childrens Hospital Boston Presents at the Society for Adolescent Medicine Annual Meeting
8. Monogram Presents Results of First ETag Breast Cancer Studies
9. Novagali Pharma Presents Phase III Clinical Trial of Vekacia(R) for Vernal Keratoconjunctivitis
10. Recovering Pranab Mukherjee Likely to Be Discharged Tomorrow
11. Earth Day Celebrated With Hopes of a Greener Tomorrow
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2019)... ... September 11, 2019 , ... A September 2 article ... weight loss surgery were significantly less likely to suffer heart attacks, strokes, kidney failure, ... bariatric surgery. Los Angeles-based weight loss surgery specialists Dr. Feiz and Associates says the ...
(Date:9/11/2019)... CITY, N.J. (PRWEB) , ... September 11, 2019 ... ... content management, will exhibit at the 2019 AHIMA Health Data and Information Conference ... encouraged to stop by booth #505 to learn more about GRM’s healthcare ...
(Date:9/11/2019)... ... September 11, 2019 , ... ... challenges facing specialty healthcare, announces the issuance of a patent to reduce the ... payment plan for both time-of-service and post visit patient statements. , At the ...
(Date:9/11/2019)... ... September 10, 2019 , ... Women’s Excellence is excited to ... location at 32686 Woodward Ave, Suite 103, Royal Oak, MI 48073 in the heart ... location offers comprehensive women’s health services in a contemporary, spa-like atmosphere. We are ...
(Date:9/11/2019)... ... September 10, 2019 , ... ... problems facing the ever-changing corporate landscape, Mediaplanet today announces the launch of ... With topics ranging from the importance of candid one-on-one conversations, ideas for ...
Breaking Medicine News(10 mins):
(Date:9/11/2019)... ... 2019 , ... A new study published today in JAMA ... identity from transgender to cisgender is associated with a range of adverse mental ... Fenway Institute, Massachusetts General Hospital (Harvard Medical School), and McLean Hospital (Harvard Medical ...
(Date:9/11/2019)... ... September 11, 2019 , ... ... a period of rediscovery and attraction from big pharma, nutraceutical manufacturers, food companies, ... and North American use rates are expected to rise as access to hemp-derived ...
(Date:9/11/2019)... (PRWEB) , ... September 11, 2019 , ... ... today announced that elder care innovator HomeThrive has selected LifePod’s voice-first service for ... as unpaid caregivers to adults over the age of 50, demand has steadily ...
Breaking Medicine Technology: